Results 151 to 160 of about 11,829,060 (287)

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

Pharmacists' Knowledge, Attitude, and Practice of Medication Therapy Management: A Systematic Review. [PDF]

Healthcare (Basel), 2022
Rendrayani F, Alfian SD, Wahyudin W, Puspitasari IM.   +3 more
europepmc   +1 more source

Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy

Molecular Oncology, EarlyView.
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley   +1 more source

Risk stratification-based tiered medication therapy management for outpatients with asthma: a practical prospective study. [PDF]

Front Pharmacol
Lian Y, Xiong S, Zhao H, Deng Y, Wu H.
europepmc   +1 more source

Racial and ethnic disparities in the enrolment of medicare medication therapy management programs. [PDF]

J Pharm Health Serv Res, 2023
Garuccio J, Tsang CCS, Wan JY, Shih YCT, Chisholm-Burns MA, Dagogo-Jack S, Cushman WC, Dong X, Browning JA, Zeng R, Wang J.   +10 more
europepmc   +1 more source

USP7 inhibits FOXO1 activity in chronic lymphocytic leukaemia cells enhancing cell survival

Molecular Oncology, EarlyView.
CLL cells rely on BCR‐mediated signalling for survival and proliferation in part through suppression of FOXO1. FOXO1 activity is regulated by a plethora of post‐translational modifications including phosphorylation and ubiquitination. We demonstrated that dual inhibition of BCR signalling and the deubiquitinase USP7 activates FOXO1, modulating its ...
Hassan N.B. Almuhanna, Jodie Hay, Michael W. Moles, Lucy Clarke, Jennifer Cassels, Alison Sefcick, Alison M. McCaig, Heather G. Jørgensen, Alison M. Michie   +8 more
wiley   +1 more source

Medication Therapy Management Guided by TIME Criteria in Nursing Home Residents: A Before-After Observational Study. [PDF]

J Clin Med
Avci S, Gundogan A, Karaakin Dinar AB, Erol A, Yazici M, Mert CB, Cingar Alpay K, Avlagi GK, Oren Celik MM, Erdincler UD, Bahat G.   +10 more
europepmc   +1 more source

Knowledge, attitude, and practice of medication therapy management: a national survey among pharmacists in Indonesia. [PDF]

Front Public Health, 2023
Rendrayani F, Alfian SD, Wahyudin W, Puspitasari IM.   +3 more
europepmc   +1 more source

Attitudes of cancer patients toward ctDNA‐based liquid biopsy for follow‐up

Molecular Oncology, EarlyView.
This mixed‐methods study explored cancer patients' experiences, knowledge, and preferences regarding ctDNA‐based liquid biopsy for follow‐up. Awareness of ctDNA was low and recall of previous liquid biopsy was imperfect, yet acceptance was high.
Siddharth Chhajlani, Laura Mariën, Caro De Weerdt, Sanne Wouters, Laure‐Anne Teuwen, Hans Prenen, Katleen Janssens, Timon Vandamme   +7 more
wiley   +1 more source